A Randomized, Placebo-Controlled Trial of Nandrolone Decanoate in Human Immunodeficiency Virus-Infected Men with Mild to Moderate Weight Loss with Recombinant Human Growth Hormone as Active Reference Treatment

Objective: We compared the effectiveness of a biweekly regimen of 150 mg nandrolone with placebo in HIV-infected men with mild to moderate weight loss and contrasted its effects against a Food and Drug Administration-approved regimen of recombinant human (rh)GH. Methods: In this placebo-controlled,...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of clinical endocrinology and metabolism Vol. 90; no. 8; pp. 4474 - 4482
Main Authors:	Storer, Thomas W., Woodhouse, Linda J., Sattler, Fred, Singh, Atam B., Schroeder, E. Todd, Beck, Keith, Padero, MaClara, Mac, Phong, Yarasheski, Kevin E., Geurts, Paul, Willemsen, Arnold, Harms, Marloes K., Bhasin, Shalender
Format:	Journal Article
Language:	English
Published:	Bethesda, MD Endocrine Society 01-08-2005
Subjects:	Adipose Tissue - drug effects Adult Anabolic Agents - administration & dosage Appetite - drug effects Biological and medical sciences Blood Glucose - drug effects Body Composition - drug effects Endocrinopathies Fundamental and applied biological sciences. Psychology Gonadal Steroid Hormones - blood HIV Wasting Syndrome - drug therapy Human Growth Hormone - administration & dosage Human immunodeficiency virus Humans Insulin Resistance Male Medical sciences Middle Aged Muscle, Skeletal - drug effects Muscle, Skeletal - physiology Nandrolone - administration & dosage Nandrolone - analogs & derivatives Physical Endurance - drug effects Placebos Quality of Life Severity of Illness Index Sexuality - drug effects Vertebrates: endocrinology Weight Loss - drug effects Steroid Human Immunopathology Reference Weight loss Somatotropin hormone Male AIDS Immune deficiency Infection Nandrolone decanoate Treatment Adenohypophyseal hormone Viral disease Placebo Randomised controlled trial Adult Clinical trial Recombinant protein Endocrinology
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objective: We compared the effectiveness of a biweekly regimen of 150 mg nandrolone with placebo in HIV-infected men with mild to moderate weight loss and contrasted its effects against a Food and Drug Administration-approved regimen of recombinant human (rh)GH. Methods: In this placebo-controlled, randomized, 12-wk trial, placebo and nandrolone (150 mg im biweekly) were administered double blind, and rhGH (6 mg sc daily) was administered in an open-label manner. Participants were HIV-infected men with 5–15% weight loss over 6 months and on stable antiretroviral therapy for more than 12 wk. Lean body mass (LBM), muscle performance, physical function, endurance, hormone levels, insulin sensitivity, sexual function, quality of life, and appetite were assessed at baseline and after 12 wk. Results: Nandrolone administration was associated with a greater increase in LBM (+1.6 ± 0.3 kg) by dual-energy x-ray absorptiometry scan than placebo (+0.4 ± 0.3 kg; P < 0.05); however, the change in LBMs with nandrolone was not significantly different from rhGH (+2.5 ± 0.3 kg). Nandrolone administration was also associated with significantly greater gains in fat-free mass (+1.6 ± 0.3 kg), body cell mass (+1.0 ± 0.2 kg), and intracellular water (+0.9 ± 0.2 kg) than placebo; these changes in the nandrolone group were not significantly different from the rhGH group. rhGH administration was associated with greater loss of whole body fat mass and higher frequency of drug-related adverse effects and treatment discontinuations than nandrolone and placebo and a greater increase in extracellular water than nandrolone. Nandrolone treatment was associated with greater improvements in perception of health than rhGH and sexual function than placebo. The cachexia/anorexia scores, health care resource use, and insulin sensitivity did not significantly change. Conclusion: We conclude that nandrolone is superior to placebo and not significantly different from a Food and Drug Administration-approved regimen of rhGH in improving lean body mass in HIV-infected men with mild to moderate weight loss.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-News-3
ISSN:	0021-972X 1945-7197
DOI:	10.1210/jc.2005-0275